MedTrace Logo

A Randomized Trial of 24-Week Versus 48-Week Courses of Peginterferon Plus Ribavirin for Patients With Genotype 1 Hepatitis C and IL28B CC Polymorphism

NCT01441804 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2013-10-01

No results posted yet for this study

Summary

Patients with HCV genotype 1 and IL28B CC Polymorphism who have a rapid virological response to treatment are randomised to either 24 or 48 weeks HCV treatment. Our hypothesis is that there is no important difference in effect between the two treatment effect.

Conditions

  • Chronic Hepatitis C

Interventions

DRUG

Peginterferon alfa2a

patients receive a dose of 180 µg of PEGASYS once a week for 24 weeks

DRUG

Ribavirin

patients receive a dose 800 to 1200 mg of ribavirin once a day(according to weight) for 24 weeks

DRUG

Peginterferon alfa2a

patients receive a dose of 180 µg of PEGASYS once a week for 48 weeks

DRUG

Ribavirin

patients receive a dose 800 to 1200 mg of ribavirin once a day(according to weight) for 48 weeks

Sponsors & Collaborators

  • Third Affiliated Hospital, Sun Yat-Sen University

    lead OTHER

Principal Investigators

  • Gao Zhiliang, Doctor · The Third Affliated Hospital of Sun Yat-sen University

  • Zhao Zhixin, Doctor · The Third Affliated Hospital of Sun Yat-sen University

  • Zhang Xiaohong, Doctor · The Third Affliated Hospital of Sun Yat-sen University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
16 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-05-31
Primary Completion
2014-05-31
Completion
2014-08-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01441804 on ClinicalTrials.gov